With Genio®, Nyxoah has reinvented sleep for patients with moderate to severe Obstructive Sleep Apnea (OSA). Genio® is a comfortable and elegant treatment for obstructive sleep apnea for people who cannot tolerate, have failed or refused CPAP therapy.
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution, Genio®, uses hypoglossal nerve stimulation, an alternative to CPAP therapy, to treat obstructive sleep apnea, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Obstructive sleep apnea (OSA) is the most common sleep disordered breathing condition, affecting globally around 936 million people between 30 and 69 years of age, of whom 425 million suffer from moderate to severe OSA, requiring treatment*.
Left untreated, OSA is associated with increased mortality risk* and comorbidities, including cardiovascular diseases, depression and stroke.
Clinical studies have shown that the mortality rate of non-treated patients suffering from OSA increases significantly over time* . Untreated OSA is associated with a two-times more risk of stroke* and five-times more risk of cardiovascular mortality*. OSA increases the risk of heart failure by 140%*.